Machina Capital S.A.S. Sells 12,740 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Machina Capital S.A.S. cut its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 44.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,997 shares of the biopharmaceutical company's stock after selling 12,740 shares during the period. Machina Capital S.A.S.'s holdings in Royalty Pharma were worth $408,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Brooklyn Investment Group boosted its stake in shares of Royalty Pharma by 1,006.9% in the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 876 shares during the period. Allworth Financial LP grew its holdings in shares of Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 877 shares in the last quarter. Riverview Trust Co increased its position in shares of Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,186 shares during the period. Fifth Third Bancorp increased its position in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 997 shares during the period. Finally, Blue Trust Inc. raised its stake in Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $41.60.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX traded up $0.39 during mid-day trading on Wednesday, hitting $32.85. 3,446,938 shares of the stock traded hands, compared to its average volume of 2,828,847. The company has a market cap of $18.94 billion, a PE ratio of 22.66, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a 50 day simple moving average of $31.16 and a two-hundred day simple moving average of $28.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a $0.22 dividend. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date was Friday, February 21st. Royalty Pharma's payout ratio is currently 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.